BioAge Labs Inc.(BIOA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BIOA BioAge Labs Inc.

Market Closed 12-12 16:00:00 EST

12.88

+0.13

+1.02%

盘后12.88

+0.000.00%

16:10 EST

High13.06	Low12.55	Vol327.65K
Open12.72	D1 Closing12.75	Amplitude3.96%
Mkt Cap461.81M	Tradable Cap313.10M	Total Shares35.86M
T/O4.23M	T/O Rate1.35%	Tradable Shares24.31M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BIOA","market":"US","secType":"STK","nameCN":"BioAge Labs Inc.","latestPrice":12.88,"timestamp":1765573200000,"preClose":12.75,"halted":0,"volume":327653,"hourTrading":{"tag":"盘后","latestPrice":12.88,"preClose":12.88,"latestTime":"16:10 EST","volume":2843,"amount":36617.84,"timestamp":1765573803894},"delay":0,"floatShares":24308899,"shares":35855037,"eps":-2.111699,"marketStatus":"Market Closed","change":0.13,"latestTime":"12-12 16:00:00 EST","open":12.72,"high":13.0554,"low":12.55,"amount":4231761.476,"amplitude":0.039639,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.111699,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1727323200000,"exchange":"NASDAQ","adjPreClose":12.75,"preHourTrading":{"tag":"盘前","latestPrice":12.5,"preClose":12.75,"latestTime":"09:28 EST","volume":1503,"amount":18722.609478,"timestamp":1765549680065},"postHourTrading":{"tag":"盘后","latestPrice":12.88,"preClose":12.88,"latestTime":"16:10 EST","volume":2843,"amount":36617.84,"timestamp":1765573803894},"volumeRatio":0.41360625247781024,"impliedVol":1.0216,"impliedVolPercentile":0.7062},"requestUrl":"/m/hq/s/BIOA","defaultTab":"news","newsList":[{"id":"2590541303","title":"BioAge Labs Chief Medical Officer Paul D. Rubin Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590541303","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590541303?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:21","pubTimestamp":1765488107,"startTime":"0","endTime":"0","summary":"Paul D. Rubin, Chief Medical Officer of Bioage Labs Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 11, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL6kyPs6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BioAge Labs Chief Medical Officer Paul D. Rubin Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA","BK4007"],"gpt_icon":0},{"id":"2590635748","title":"BioAge Labs Raised to Equal-Weight From Underweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2590635748","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590635748?lang=en_us&edition=fundamental","pubTime":"2025-12-09 01:17","pubTimestamp":1765214220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BIOA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 08, 2025 12:17 ET (17:17 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA"],"gpt_icon":0},{"id":"2589843146","title":"BioAge Labs Chief Medical Officer Paul D. Rubin Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2589843146","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589843146?lang=en_us&edition=fundamental","pubTime":"2025-12-06 07:21","pubTimestamp":1764976875,"startTime":"0","endTime":"0","summary":"Paul D. Rubin, Chief Medical Officer of Bioage Labs Inc., has reported the disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 05, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL3lZGrM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BioAge Labs Chief Medical Officer Paul D. Rubin Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BIOA"],"gpt_icon":0},{"id":"2588887015","title":"BRIEF-Bioage Labs Inc - Announces Positive Interim Phase 1 Data For BGE-102","url":"https://stock-news.laohu8.com/highlight/detail?id=2588887015","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588887015?lang=en_us&edition=fundamental","pubTime":"2025-12-04 22:09","pubTimestamp":1764857391,"startTime":"0","endTime":"0","summary":"BRIEF-Bioage Labs Inc - Announces Positive Interim Phase 1 Data For BGE-102Dec 4 (Reuters) - BIOAGE Labs Inc BIOA.O:BIOAGE LABS INC - ANNOUNCES POSITIVE INTERIM PHASE 1 DATA FOR BGE-102, A NOVEL BRAIN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA0DA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BIOA"],"gpt_icon":0},{"id":"2588887744","title":"Bioage Labs Inc - Bge-102 Well-Tolerated in Sad and Initial Mad Cohorts, With a Pharmacokinetic Profile Supporting Once-Daily Oral Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2588887744","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588887744?lang=en_us&edition=fundamental","pubTime":"2025-12-04 22:08","pubTimestamp":1764857327,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA0DA:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIOA","BK4007"],"gpt_icon":0},{"id":"2588791887","title":"Bioage Labs Inc - Announces Positive Interim Phase 1 Data for Bge-102, a Novel Brain-Penetrant Nlrp3 Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2588791887","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588791887?lang=en_us&edition=fundamental","pubTime":"2025-12-04 22:08","pubTimestamp":1764857327,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA0DA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIOA","BK4007"],"gpt_icon":0},{"id":"2588988710","title":"BioAge Labs Reports Positive Interim Phase 1 Results for BGE-102 NLRP3 Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2588988710","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588988710?lang=en_us&edition=fundamental","pubTime":"2025-12-04 22:00","pubTimestamp":1764856826,"startTime":"0","endTime":"0","summary":"BioAge Labs Inc. has announced positive interim results from an ongoing Phase 1 clinical trial of BGE-102, a novel orally available, brain-penetrant NLRP3 inhibitor. The study's initial findings indicate that BGE-102 was well tolerated across single and multiple ascending dose cohorts, with a pharmacokinetic profile supporting once-daily oral dosing. BGE-102 demonstrated strong target engagement, achieving 90-98% suppression of IL-1β at Day 14, and high brain penetration at doses of 60 mg and above. The company is expanding the Phase 1 trial to include multiple ascending dose cohorts in participants with obesity and elevated hsCRP, with data from these cohorts anticipated in the first half of 2026. Full safety and efficacy analyses will follow after database lock and unblinding.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informati","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL1zXW1N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA","BK4588","IE00B64PRP62.GBP","BK4585","LU2095319765.USD","IE00BGHQF748.EUR","BK4112","LU2210149790.SGD","LU0314104364.USD","LU2210150020.SGD","IE00BKPKM429.USD","BK4007","IE00B3QW5Z07.USD","NDAQ"],"gpt_icon":0},{"id":"2581886318","title":"BioAge Labs to Present at Jefferies Global Healthcare Conference in London","url":"https://stock-news.laohu8.com/highlight/detail?id=2581886318","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581886318?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:00","pubTimestamp":1762524021,"startTime":"0","endTime":"0","summary":"BioAge Labs Inc., a clinical-stage biotechnology company focused on developing therapies for metabolic diseases targeting the biology of human aging, will present at the Jefferies Global Healthcare Conference in London from November 17-20, 2025. CEO Kristen Fortney and CFO Dov Goldstein are scheduled to participate in a fireside chat on November 17 and will join one-on-one meetings during the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief via GlobeNewswire  on November 07, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL89BVZr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210150020.SGD","LU2095319765.USD","BK4007","BIOA","BK4585","IE00BKPKM429.USD","BK4112","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU0314104364.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","NDAQ"],"gpt_icon":0},{"id":"2581780190","title":"BioAge Labs Advances Clinical Programs Amid Financial Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2581780190","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581780190?lang=en_us&edition=fundamental","pubTime":"2025-11-07 14:03","pubTimestamp":1762495412,"startTime":"0","endTime":"0","summary":"BioAge Labs, Inc. ( ($BIOA) ) has released its Q3 earnings. Here is a breakdown of the information BioAge Labs, Inc. presented to its investors. Bi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bioage-labs-advances-clinical-programs-amid-financial-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bioage-labs-advances-clinical-programs-amid-financial-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIOA","BK4007","PRGS","LU2065732104.USD","BK4097"],"gpt_icon":0},{"id":"2581046918","title":"Bioage Labs Q3 EPS $(0.56) Beats $(0.58) Estimate, Sales $2.054M","url":"https://stock-news.laohu8.com/highlight/detail?id=2581046918","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581046918?lang=en_us&edition=fundamental","pubTime":"2025-11-07 06:05","pubTimestamp":1762466746,"startTime":"0","endTime":"0","summary":"Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.58) by 3.45 percent. This is a 91.64 percent increase over losses of $(6.70) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48706450/bioage-labs-q3-eps-0-56-beats-0-58-estimate-sales-2-054m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Bioage Labs Q3 EPS $(0.56) Beats $(0.58) Estimate, Sales $2.054M","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TQQQ","QID","USJW.SI","QLD","USAW.SI","PSQ","BK4007","TSYW.SI","MNQmain",".IXIC","SQQQ","NVIW.SI","NQmain","BIOA"],"gpt_icon":0},{"id":"2581045158","title":"BioAge Labs Doses First Participant in BGE-102 Phase 1 Trial and Reports $2.1 Million Q3 Collaboration Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2581045158","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581045158?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:48","pubTimestamp":1762465725,"startTime":"0","endTime":"0","summary":"BioAge Labs Inc., a clinical-stage biopharmaceutical company focused on therapies targeting metabolic diseases and human aging, reported its third quarter 2025 financial results and provided business updates. The company announced the dosing of the first participant in its Phase 1 trial of BGE-102, an oral CNS-penetrant NLRP3 inhibitor, with initial single ascending dose data expected by the end of the year. BioAge also continued progress on its oral and parenteral APJ agonist programs, targeting investigational new drug  submissions in 2026. Collaboration revenue for the quarter ended September 30, 2025, was $2.1 million, compared to no revenue in the same period of 2024. This increase was attributed to revenue recognized under BioAge's multi-year research collaboration with Novartis, initiated in 2025. As of September 30, 2025, the company reported approximately $295.9 million in cash, cash equivalents, and marketable securities, which it estimates will be sufficient to fund operatio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDLbGdmn6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BKPKM429.USD","LU2095319765.USD","LU2210150020.SGD","BK4112","BIOA","IE00B3QW5Z07.USD","LU0314104364.USD","IE00B64PRP62.GBP","BK4588","NDAQ","IE00BGHQF748.EUR","BK4007","LU2210149790.SGD"],"gpt_icon":0},{"id":"2581004559","title":"Bioage Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2581004559","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581004559?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:45","pubTimestamp":1762465500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUA91RKJL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIOA","BK4007"],"gpt_icon":0},{"id":"2581065756","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2581065756","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581065756?lang=en_us&edition=fundamental","pubTime":"2025-11-06 19:00","pubTimestamp":1762426800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·A-Mark Precs Mtl                                1Q       .60    4:05 PM. ·Achve Life Scncs                                3Q      (.24)   7:30 AM. ·Air Pdts and Chem                                4Q      3.38    6:00 AM. ·Alpha Metall Rsrcs                               3Q      (.52)   7:30 AM. ·Altice USA Inc.                                 3Q      (.06)   7:00 AM","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMN","ACIW","APPN","APD","ALTG","ASTH","BIOA","ATLC","AMRK","ARHS","ATHM","AVAH","AMR","BLZE","AFRM","AMTX","ASPN","ABCL","CARL","ALLO","AURA","APYX","AMPX","ABL","OPTU","AEE","AMBQ","ADV","AGO","ALG","ATUS","AKAM","ASMB","GOOS","AAON","AMPH","ACHV","BIRD","AAOI","ATYR","AHR","ACRV","APLT","ALT","ARLO","ABNB","ALRM","AMLX","ADVM","AORT"],"gpt_icon":1},{"id":"2581354701","title":"BIOAGE Labs Inc  expected to post a loss of 58 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581354701","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581354701?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:06","pubTimestamp":1762376782,"startTime":"0","endTime":"0","summary":"BIOAGE Labs Inc  expected to post a loss of58cents a share - Earnings Preview BIOAGE Labs Inc BIOA.OQ BIOA.O is expected to  show a rise in quarterly revenue when it reports  results on November 7 (es","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL8N3WH379:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA","BK4007"],"gpt_icon":0},{"id":"2579557133","title":"BioAge Labs Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2579557133","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579557133?lang=en_us&edition=fundamental","pubTime":"2025-10-30 04:06","pubTimestamp":1761768360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BIOA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 29, 2025 16:06 ET (20:06 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA"],"gpt_icon":0},{"id":"2577666373","title":"U.S. RESEARCH ROUNDUP-Avery Dennison, Expedia Group, Hologic","url":"https://stock-news.laohu8.com/highlight/detail?id=2577666373","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577666373?lang=en_us&edition=fundamental","pubTime":"2025-10-23 15:30","pubTimestamp":1761204653,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Avery Dennison, Expedia Group, Hologic Oct 23 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Aver","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nL8N3W40G6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023250843.SGD","DECK","FI","ALKS","BK4150","BSX","KREF","NRIX","HOLX","LU1861217088.USD","GPC","GEV","JAZZ","LII","MOS","APH","FULT","T","LRCX","BKNG","CBU","EXPE","AVY","GPOR","LVS","LU2125909247.SGD","CME","MRNA","LU1815336760.USD","IE00BZ1G4Q59.USD","LU2357125470.USD","OFG","BIOA","DKNG","GSHD","RL","IDYA","CPRI","ELV","FRPT","LU2023250504.SGD","MBCN","BHB","ARCT","LU0477156797.USD","NTRS","IE00BJJMRZ35.SGD","LC","CCI","HLT"],"gpt_icon":0},{"id":"2577986318","title":"BioAge Labs Shares Rise After Citigroup Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2577986318","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577986318?lang=en_us&edition=fundamental","pubTime":"2025-10-23 02:39","pubTimestamp":1761158351,"startTime":"0","endTime":"0","summary":"BioAge Labs  shares were up over 13% in recent Wednesday trading after Citigroup upgraded the stock to buy from neutral and boosted its price target to $10 from $5.Trading volume stood at more than 1.0 million shares, compared with a daily average of about 167,000.Price: 6.00, Change: +0.70, Percent Change: +13.21","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BIOA"],"gpt_icon":0},{"id":"2577910366","title":"BioAge Labs Raised to Buy From Neutral by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2577910366","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577910366?lang=en_us&edition=fundamental","pubTime":"2025-10-22 19:31","pubTimestamp":1761132660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BIOA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 22, 2025 07:31 ET (11:31 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA"],"gpt_icon":0},{"id":"2577350984","title":"Bioage Labs Shares Jump 7.7% Premarket After Citigroup Upgrade, PT Hike","url":"https://stock-news.laohu8.com/highlight/detail?id=2577350984","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577350984?lang=en_us&edition=fundamental","pubTime":"2025-10-22 18:14","pubTimestamp":1761128095,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nFWN3W228J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BIOA"],"gpt_icon":0},{"id":"2577354044","title":"BioAge Labs upgraded to Buy from Neutral at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2577354044","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577354044?lang=en_us&edition=fundamental","pubTime":"2025-10-22 17:10","pubTimestamp":1761124209,"startTime":"0","endTime":"0","summary":"Citi upgraded BioAge Labs (BIOA) to Buy from Neutral with a price target of $10, up from $5. The firm believes the company’s BGE-102 can become a “...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioage-labs-upgraded-to-buy-from-neutral-at-citi-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioage-labs-upgraded-to-buy-from-neutral-at-citi-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIOA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://bioagelabs.com","stockEarnings":[{"period":"1week","weight":0.1094},{"period":"1month","weight":0.608},{"period":"3month","weight":1.6833},{"period":"6month","weight":1.8496},{"period":"1year","weight":1.8061},{"period":"ytd","weight":1.2245}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":" ","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.008123},{"month":2,"riseRate":0.4,"avgChangeRate":-0.16094},{"month":3,"riseRate":0.2,"avgChangeRate":-0.091972},{"month":4,"riseRate":0.4,"avgChangeRate":-0.044244},{"month":5,"riseRate":0,"avgChangeRate":-0.19738},{"month":6,"riseRate":0.25,"avgChangeRate":0.003055},{"month":7,"riseRate":0.4,"avgChangeRate":-0.005696},{"month":8,"riseRate":0.4,"avgChangeRate":-0.229124},{"month":9,"riseRate":0.6,"avgChangeRate":0.004924},{"month":10,"riseRate":0.8,"avgChangeRate":0.181962},{"month":11,"riseRate":0.6,"avgChangeRate":0.056827},{"month":12,"riseRate":0.2,"avgChangeRate":-0.087267}],"exchange":"NASDAQ","name":"BioAge Labs Inc.","nameEN":"BioAge Labs Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioAge Labs Inc.(BIOA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BioAge Labs Inc.(BIOA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BioAge Labs Inc.,BIOA,BioAge Labs Inc.股票,BioAge Labs Inc.股票老虎,BioAge Labs Inc.股票老虎国际,BioAge Labs Inc.行情,BioAge Labs Inc.股票行情,BioAge Labs Inc.股价,BioAge Labs Inc.股市,BioAge Labs Inc.股票价格,BioAge Labs Inc.股票交易,BioAge Labs Inc.股票购买,BioAge Labs Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioAge Labs Inc.(BIOA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BioAge Labs Inc.(BIOA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}